In one study, autologous tumor cell vaccines via EBV/liposomes were designed to secrete IL-12 and IL-18 (B16/mIL-12+mIL-18), and repeated immunization showed strong tumor inhibition in a B16 melanoma model, accompanied by high IFN-γ production [250]. This evidence concerns the gene SPRR2A and neoplasm.